Treatment with teclistamab, administered subcutaneously at a dose of 1500 µg/kg once weekly, led to a high response rate and an encouraging safety profile in patients with relapsed/refractory multiple myeloma.
Recent Content
- Ovarian cancer drug lira-cel extends survival ‘far longer’ than expected
- The impact of cardiac amyloidosis on patients with multiple myeloma: a systematic review and meta-analysis
- (no title)
- Myeloma treatment anito-cel shows potential for fewer side effects
- FDA grants orphan drug status to new treatment for agressive blood cancers
- FDA gives green light to first human trial testing cancer drug GTB-5550
- Tumour-intrinsic features shape T cell differentiation through precursor to symptomatic multiple myeloma
- (no title)
- (no title)
- Scientists test treatment strategy using ‘glioblastoma on a chip’